As we were particularly interested in genes relevant to drug disposition and toxicity, we filtered identified eQTLs according to their potential relevance in the context of ADME processes. We compiled an ADME gene set comprising 682 genes (Supplementary Table S3) from various resources including the PharmaADME Working Group list of ADME genes (http://pharmaadme.org/), the NURSA (Nuclear Receptor Signaling Atlas) Consortium40 and the PharmGKB knowledge base41 (http://www.pharmgkb.org/). By requesting either SNP or trait gene or both to be an ADME gene, we identified a total of 95 significant associations, of which 89 were cis- or presumably cis-acting and 6 were trans- or presumably trans-acting. Table 1 shows 21 associations that could be validated by comparison with the Seattle study (see below), and Table 2 shows the other 74 ADME associations uniquely identified in our study.
